Readoutin 104d
Pierre Fabre Medicament — Encorafenib and Binimetinib
Phase 3 primary completion: Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation..
- Date
- Mar 2027
- Type
- Readout
- Indication
- Melanoma
Readoutin 104d
Phase 3 primary completion: Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation..
The weekly brief is free. Pro adds reminders 7 days and 1 day before.